NCT06438172 - A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension | Biotech Hunter

Enrollment

249

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions

Hypertension

Interventions

DRUG

HCP1803-3

Take it once daily for 8 weeks orally.

DRUG

RLD2001-1

Take it once daily for 8 weeks orally.

DRUG

HPP2003-3

Placebo drug. Take it once daily for 8 weeks orally.

DRUG

HPP2002-1

Placebo drug. Take it once daily for 8 weeks orally.

Trial Locations (1)

Donggguk University Ilsan Hospital, Goyang-si